Related Experiment Video
Updated: Jul 13, 2025
15:53
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
15.0K
Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase
Gartrell C Bowling1,2, Piragash Swargaloganathan1, Carly Heintz1
1School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA.
Cancers
|October 14, 2023
Summary
Poly ADP-ribose polymerase inhibitors (PARPis) increase the risk of anemia, thrombocytopenia, and neutropenia in prostate cancer patients. This review highlights significant hematological adverse events associated with PARPi therapy.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Poly ADP-ribose polymerase inhibitors (PARPis) are a key treatment for metastatic castration-resistant prostate cancer (mCRPC).
- Unlike hormone therapies, PARPis can cause drug-related hematological adverse events.
Purpose of the Study:
- To systematically review and analyze evidence on hematological toxicities (anemia, thrombocytopenia, neutropenia) associated with PARPi use in prostate cancer.
- To quantify the risk of these toxicities using meta-analysis.
Main Methods:
- A systematic review and meta-analysis of phase II and III randomized controlled trials (RCTs) of PARPis in prostate cancer.
- Searched PubMed, Embase, and Ovid from inception to June 9, 2023.
- Used Mantel-Haenszel method to calculate risk ratios (RR) and 95% confidence intervals (CI) for all-grade and high-grade hematological toxicities.
Main Results:
- PARPi use significantly increased the risk of all-grade anemia (RR, 3.37), thrombocytopenia (RR, 4.54), and neutropenia (RR, 3.11) compared to placebo or other non-PARPi treatments.
- High-grade anemia (RR, 6.94) and thrombocytopenia (RR, 5.52) also showed significant increases.
- High-grade neutropenia did not show a statistically significant association (RR, 3.63; p = 0.10).
Conclusions:
- PARPis are associated with a notable increase in hematological adverse events in prostate cancer patients.
- Further pooled RCTs are needed to refine understanding and inform clinical decision-making and management strategies for these toxicities.
Keywords:
CRPCPARP inhibitorsPoly ADP-ribose polymerase (PARP)niraparibolaparibprostate cancerrucaparibtalazoparibveliparibMore Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
165
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
165
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
192
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
538
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
538
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K